Amgen’s Denosumab, GTx’s Toremifene Keep Pace At ASCO On Prevention Of Bone Fractures In Prostate Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Both firms have October user fee dates for prevention of bone fracture risk in prostate cancer patients on androgen deprivation therapy, and both report favorable incremental data.
You may also be interested in...
FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says
Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.
FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says
Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.
FDA "Complete Response" On Toremifene Moves The Goal Posts, GTx CEO Says
GTx was taken by surprise with FDA's decision to issue a "complete response" letter for the firm's selective estrogen receptor modulator toremifene 80 mg - a drug whose clinical development program was designed with the agency's help under a Special Protocol Assessment